Medical Technology

@xconomy.com 3 years ago

FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures

@xconomy.com 4 years ago

Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More

@xconomy.com 4 years ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 4 years ago

Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

@xconomy.com 4 years ago

Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus

@xconomy.com 4 years ago

Revolution Medicines Maps Out an IPO to Reach Cancer’s Frontiers

@xconomy.com 5 years ago

With OneOncology, Flatiron and Cancer Docs Aim to Boost Community Care